Thermostabilization of inactivated polio vaccine in PLGA-based microspheres for pulsatile release

被引:46
|
作者
Tzeng, Stephany Y. [1 ]
Guarecuco, Rohiverth [1 ]
McHugh, Kevin J. [1 ]
Rose, Sviatlana [1 ]
Rosenberg, Evan M. [1 ]
Zeng, Yingying [1 ]
Langer, Robert [1 ]
Jaklenec, Ana [1 ]
机构
[1] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA
关键词
Drug delivery; Vaccine delivery; Single-administration vaccines; Controlled release kinetics; Vaccine stability; BIODEGRADABLE MICROSPHERES; POLYMER MICROSPHERES; THERMAL-STABILITY; DRUG-DELIVERY; PROTEIN; MICROENCAPSULATION; STABILIZATION; IMMUNIZATION; MECHANISMS; CHALLENGES;
D O I
10.1016/j.jconrel.2016.05.012
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Vaccines are a critical clinical tool in preventing illness and death due to infectious diseases and are regularly administered to children and adults across the globe. In order to obtain full protection from many vaccines, an individual needs to receive multiple doses over the course of months. However, vaccine administration in developing countries is limited by the difficulty in consistently delivering a second or third dose, and some vaccines, including the inactivated polio vaccine (IPV), must be injected more than once for efficacy. In addition, IPV does not remain stable over time at elevated temperatures, such as those it would encounter over time in the body if it were to be injected as a single-administration vaccine. In this manuscript, we describe microspheres composed of poly(lactic-co-glycolic acid) (PLGA) that can encapsulate IPV along with stabilizing excipients and release immunogenic IPV over the course of several weeks. Additionally, pH-sensitive, cationic dopants such as Eudragit E polymer caused clinically relevant amounts of stable IPV release upon degradation of the PLGA matrix. Specifically, IPV was released in two separate bursts, mimicking the delivery of two boluses approximately one month apart. In one of our top formulations, 1.4, 1.1, and 1.2 doses of the IPV serotype 1, 2, and 3, respectively, were released within the first few days from 50 mg of particles. During the delayed, second burst, 0.5, 0.8, and 0.6 doses of each serotype, respectively, were released; thus, 50 mg of these particles released approximately two clinical doses spaced a month apart. Immunization of rats with the leading microsphere formulation showed more robust and long-lasting humoral immune response compared to a single bolus injection and was statistically non-inferior from two bolus injections spaced 1 month apart. By minimizing the number of administrations of a vaccine, such as IPV, this technology can serve as a tool to aid in the eradication of polio and other infectious diseases for the improvement of global health. (C) 2016 The Authors. Published by Elsevier B.V.
引用
收藏
页码:101 / 113
页数:13
相关论文
共 21 条
  • [1] Optimising the controlled release of dexamethasone from a new generation of PLGA-based microspheres intended for intravitreal administration
    Rodriguez Villanueva, Javier
    Bravo-Osuna, Irene
    Herrero-Vanrell, Rocio
    Molina Martinez, Irene Teresa
    Guzman Navarro, Manuel
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 92 : 287 - 297
  • [2] Immunogenicity of pulsatile-release PLGA microspheres for single-injection vaccination
    Guarecuco, Rohiverth
    Lul, Jennifer
    McHugh, Kevin J.
    Norman, James J.
    Thapa, Lavanya S.
    Lydon, Emily
    Langer, Robert
    Jaklenec, Ana
    VACCINE, 2018, 36 (22) : 3161 - 3168
  • [3] PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application
    Su, Yue
    Zhang, Bolun
    Sun, Ruowei
    Liu, Wenfang
    Zhu, Qubo
    Zhang, Xun
    Wang, Rongrong
    Chen, Chuanpin
    DRUG DELIVERY, 2021, 28 (01) : 1397 - 1418
  • [4] Precise Drug Delivery by Using PLGA-Based Microspheres and Optical Manipulators
    Liu, Hongbo
    Li, Xiaojian
    Wei, Tanyong
    Xu, Shisan
    Chen, Shuxun
    Cheng, Shuk Han
    Sun, Dong
    IEEE TRANSACTIONS ON NANOBIOSCIENCE, 2020, 19 (02) : 192 - 202
  • [5] Development of PLGA-based itraconazole injectable nanospheres for sustained release
    Bian, Xiaomei
    Liang, Su
    John, Jyothy
    Hsiao, Cheng-Hui
    Wei, Xin
    Liang, Dong
    Xie, Huan
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2013, 8 : 4521 - 4531
  • [6] Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines
    Westdijk, Janny
    Brugmans, Debbie
    Martin, Javier
    van't Oever, Aart
    Bakker, Wilfried A. M.
    Levels, Lonneke
    Kersten, Gideon
    VACCINE, 2011, 29 (18) : 3390 - 3397
  • [7] In vitro evaluation of copper release from MRI-visible, PLGA-based nanospheres
    Weitz, Iris Sonia
    Perlman, Or
    Azhari, Haim
    Sivan, Sarit Sara
    JOURNAL OF MATERIALS SCIENCE, 2021, 56 (01) : 718 - 730
  • [8] Drug release from PLGA-based microparticles: Effects of the "microparticle:bulk fluid" ratio
    Klose, D.
    Siepmann, F.
    Willart, J. F.
    Descamps, M.
    Siepmann, J.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 383 (1-2) : 123 - 131
  • [9] A highly immunogenic UVC inactivated Sabin based polio vaccine
    Tobin, Gregory J.
    Tobin, John K.
    Wiggins, Taralyn J.
    Bushnell, Ruth V.
    Kozar, Arina V.
    Maale, Matthew F.
    MacLeod, David A.
    Meeks, Heather N.
    Daly, Michael J.
    Dollery, Stephen J.
    NPJ VACCINES, 2024, 9 (01)
  • [10] Interdependency of protein-release completeness and polymer degradation in PLGA-based implants
    Ghalanbor, Zahra
    Koerber, Martin
    Bodmeier, Roland
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2013, 85 (03) : 624 - 630